Defendant Name: Bristol-Myers Squibb Company

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 11012210

Initial Case Details

Legal Case Name In the Matter of Bristol-Myers Squibb Company
First Document Date 05-Oct-2015
Initial Filing Format Administrative Action
File Number 3-16881
Allegation Type Foreign Corrupt Practices Act

Violations Alleged

Exchange Act
Sec 13(b)(2)(A)
Sec 13(b)(2)(B)


First Resolution Date 05-Oct-2015
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-76073 05-Oct-2015 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On October 5, 2015, the SEC instituted settled cease-and-desist proceedings against Bristol-Myers Squibb Company (BMS). The SEC alleged that: "These proceedings arise out of violations of the internal controls and recordkeeping provisions of the Foreign Corrupt Practices Act (the 'FPCA') by BMS and its majority-owned joint venture in China. Between 2009 and 2014, BMS failed to design and maintain effective internal controls relating to interactions with health care providers ('HCPs') at state-owned and state-controlled hospitals in China."
2015-229 05-Oct-2015 Press Release--Administrative Proceeding
SEC Charges Bristol-Myers Squibb With FCPA Violations
On October 5, 2015, the SEC announced that, "New York-based pharmaceutical company Bristol-Myers Squibb has agreed to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales."